Free tool
FAERS Monitor: Cystaran
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200740 or its brand name (Cystaran, Cysteamine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
458
Serious
96
21% of reports
Hospitalization
62
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation141
- eye pain59
- ocular hyperaemia54
- photophobia36
- product dose omission issue19
- headache18
- nausea17
- vomiting17
- intentional product misuse13
- vision blurred13
- burning sensation11
- eye pruritus10
- conjunctivitis9
- diarrhoea8
- off label use8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 12 |
| 2015 | 7 |
| 2016 | 35 |
| 2017 | 74 |
| 2018 | 62 |
| 2019 | 70 |
| 2020 | 83 |
| 2021 | 6 |
| 2022 | 23 |
| 2023 | 25 |
| 2024 | 28 |
| 2025 | 31 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,701 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye irritationSignal | 141 | 112.8 | 98.3 | 15,513 |
| photophobiaSignal | 36 | 88.0 | 64.3 | 3,009 |
| ocular hyperaemiaSignal | 54 | 52.3 | 40.7 | 2,670 |
| eye painSignal | 59 | 48.1 | 37.9 | 2,677 |
| conjunctivitisSignal | 9 | 22.3 | 11.7 | 162 |
| eye pruritusSignal | 10 | 13.7 | 7.4 | 105 |
| burning sensationSignal | 11 | 7.2 | 4.0 | 53 |
| intentional product misuseSignal | 13 | 6.8 | 4.0 | 59 |
| vision blurredSignal | 13 | 4.3 | 2.5 | 30 |
| product dose omission issueSignal | 19 | 3.0 | 1.9 | 23 |
| vomiting | 17 | 1.7 | 1.0 | 4 |
| headache | 18 | 1.3 | 0.8 | 1 |
| nausea | 17 | 1.0 | 0.6 | 0 |
| diarrhoea | 8 | 0.6 | 0.3 | 2 |
| off label use | 8 | 0.4 | 0.2 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.